Literature DB >> 27387421

Discovery and antiplatelet activity of a selective PI3Kβ inhibitor (MIPS-9922).

Zhaohua Zheng1, Jo-Anne Pinson2, Simon J Mountford2, Stephanie Orive3, Simone M Schoenwaelder3, David Shackleford4, Andrew Powell4, Erin M Nelson3, Justin R Hamilton3, Shaun P Jackson3, Ian G Jennings2, Philip E Thompson5.   

Abstract

A series of amino-substituted triazines were developed and examined for PI3Kβ inhibition and anti-platelet function. Structural adaptations of a morpholine ring of the prototype pan-PI3K inhibitor ZSTK474 yielded PI3Kβ selective compounds, where the selectivity largely derives from an interaction with the non-conserved Asp862 residue, as shown by site directed mutagenesis. The most PI3Kβ selective inhibitor from the series was studied in detail through a series of in vitro and in vivo functional studies. MIPS-9922, 10 potently inhibited ADP-induced washed platelet aggregation. It also inhibited integrin αIIbβ3 activation and αIIbβ3 dependent platelet adhesion to immobilized vWF under high shear. It prevented arterial thrombus formation in the in vivo electrolytic mouse model of thrombosis without inducing prolonged bleeding or excess blood loss.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Kinase selectivity; PI3 kinase; Platelet aggregation inhibitors; Thrombosis

Mesh:

Substances:

Year:  2016        PMID: 27387421     DOI: 10.1016/j.ejmech.2016.06.010

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  7 in total

Review 1.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 2.  Therapeutic strategies for thrombosis: new targets and approaches.

Authors:  Nigel Mackman; Wolfgang Bergmeier; George A Stouffer; Jeffrey I Weitz
Journal:  Nat Rev Drug Discov       Date:  2020-03-04       Impact factor: 84.694

3.  Discovery of 5,6-diaryl-1,2,4-triazines hybrids as potential apoptosis inducers.

Authors:  Dong-Jun Fu; Jian Song; Yu-Hui Hou; Ruo-Han Zhao; Jia-Huan Li; Ruo-Wang Mao; Jia-Jia Yang; Ping Li; Xiao-Lin Zi; Zhong-Hua Li; Qing-Qing Zhang; Fei-Yan Wang; Sai-Yang Zhang; Yan-Bing Zhang; Hong-Min Liu
Journal:  Eur J Med Chem       Date:  2017-07-08       Impact factor: 6.514

Review 4.  PI3K inhibitors in thrombosis and cardiovascular disease.

Authors:  Tom N Durrant; Ingeborg Hers
Journal:  Clin Transl Med       Date:  2020-01-31

Review 5.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

6.  Structure-guided design of pure orthosteric inhibitors of αIIbβ3 that prevent thrombosis but preserve hemostasis.

Authors:  Brian D Adair; José L Alonso; Johannes van Agthoven; Vincent Hayes; Hyun Sook Ahn; I-Shing Yu; Shu-Wha Lin; Jian-Ping Xiong; Mortimer Poncz; M Amin Arnaout
Journal:  Nat Commun       Date:  2020-01-21       Impact factor: 14.919

7.  The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential.

Authors:  María N Barrachina; Irene Izquierdo; Lidia Hermida-Nogueira; Luis A Morán; Amparo Pérez; Ana B Arroyo; Nuria García-Barberá; Rocío González-Conejero; Sara Troitiño; Johannes A Eble; José Rivera; Constantino Martínez; María I Loza; Eduardo Domínguez; Ángel García
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.